Page 3 - Cidara Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Invasive candidiasis treatment rezafungin wins orphan drug status
28th January 2021
IC is a severe and life-threatening form of
Candida infection of the bloodstream and/or deep or visceral tissues.
Although there are a number of available treatments for IC, mortality rates can be as high as 40%.
Rezafungin is a novel once-weekly echinocandin – this is a class of antifungal drugs that are designed to inhibit β (1, 3)-D- glucan synthase, an enzyme which plays a key role in the integrity of the fungal cell wall.
Mundipharma and Cidara Therapeutic’s drug is currently in Phase III development to evaluate its safety, tolerability and efficacy for the treatment of candidemia and IC compared to caspofungin. ....

Brian Sheehan , European Commission , Cidara Therapeutic , பிரையன் ஷீஹான் , ஐரோப்பிய தரகு ,